EA201791875A1 - Комбинированная композиция тезофензина и бета-блокатора - Google Patents

Комбинированная композиция тезофензина и бета-блокатора

Info

Publication number
EA201791875A1
EA201791875A1 EA201791875A EA201791875A EA201791875A1 EA 201791875 A1 EA201791875 A1 EA 201791875A1 EA 201791875 A EA201791875 A EA 201791875A EA 201791875 A EA201791875 A EA 201791875A EA 201791875 A1 EA201791875 A1 EA 201791875A1
Authority
EA
Eurasian Patent Office
Prior art keywords
beta blocker
thesophenzine
combined composition
composition
obesity
Prior art date
Application number
EA201791875A
Other languages
English (en)
Other versions
EA033298B1 (ru
Inventor
Петер Г. Нильсен
Микаэл С. Томсен
Бент Хойгорд
Original Assignee
Саниона А/С
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Саниона А/С filed Critical Саниона А/С
Publication of EA201791875A1 publication Critical patent/EA201791875A1/ru
Publication of EA033298B1 publication Critical patent/EA033298B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A61K31/138—Aryloxyalkylamines, e.g. propranolol, tamoxifen, phenoxybenzamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/167—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface
    • A61K9/1676—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction with an outer layer or coating comprising drug; with chemically bound drugs or non-active substances on their surface having a drug-free core with discrete complete coating layer containing drug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A61K9/2081—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets with microcapsules or coated microparticles according to A61K9/50
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/282—Organic compounds, e.g. fats
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
    • A61K9/2846—Poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2886—Dragees; Coated pills or tablets, e.g. with film or compression coating having two or more different drug-free coatings; Tablets of the type inert core-drug layer-inactive layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Endocrinology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Данное изобретение относится к композиции с контролируемым высвобождением, содержащей активные соединения тезофензина и бета-блокатор, такой как метопролол или карведилол или их фармацевтически приемлемая соль. Данное изобретение также относится к применению композиции с контролируемым высвобождением в способе лечения диабета, ожирения или нарушения, связанного с ожирением.
EA201791875A 2015-03-03 2016-03-02 Комбинированная лекарственная форма тезофензина и метопролола EA033298B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA201570117 2015-03-03
DKPA201570644 2015-10-09
PCT/DK2016/050058 WO2016138908A1 (en) 2015-03-03 2016-03-02 Tesofensine, beta blocker combination formulation

Publications (2)

Publication Number Publication Date
EA201791875A1 true EA201791875A1 (ru) 2017-12-29
EA033298B1 EA033298B1 (ru) 2019-09-30

Family

ID=55589632

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201791875A EA033298B1 (ru) 2015-03-03 2016-03-02 Комбинированная лекарственная форма тезофензина и метопролола

Country Status (33)

Country Link
US (6) US9579288B2 (ru)
EP (1) EP3265126B1 (ru)
JP (1) JP6772430B2 (ru)
KR (1) KR101999463B1 (ru)
CN (1) CN107666913B (ru)
AU (1) AU2016228002B2 (ru)
CA (1) CA2977415A1 (ru)
CL (1) CL2017002214A1 (ru)
CO (1) CO2017009930A2 (ru)
CR (1) CR20170447A (ru)
DK (1) DK3265126T3 (ru)
DO (1) DOP2017000219A (ru)
EA (1) EA033298B1 (ru)
EC (1) ECSP17059323A (ru)
ES (1) ES2885437T3 (ru)
GT (1) GT201700194A (ru)
HK (1) HK1247127A1 (ru)
HR (1) HRP20211361T1 (ru)
HU (1) HUE055974T2 (ru)
IL (1) IL254179B (ru)
LT (1) LT3265126T (ru)
MA (1) MA41634B1 (ru)
MX (1) MX2017011257A (ru)
PE (1) PE20180187A1 (ru)
PH (1) PH12017501509B1 (ru)
PL (1) PL3265126T3 (ru)
PT (1) PT3265126T (ru)
RS (1) RS62275B1 (ru)
SA (1) SA517382209B1 (ru)
SG (1) SG11201706899VA (ru)
SI (1) SI3265126T1 (ru)
UA (1) UA122224C2 (ru)
WO (1) WO2016138908A1 (ru)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL2814473T3 (pl) * 2012-02-16 2019-06-28 Saniona A/S Kompozycje farmaceutyczne do terapii skojarzonej
LT3265126T (lt) 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija
EP3402473A1 (en) 2016-01-15 2018-11-21 Saniona A/S Tesofensine and metoprolol for treatment of hypertension
JP6612004B1 (ja) * 2018-07-31 2019-11-27 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
WO2020026471A1 (ja) * 2018-07-31 2020-02-06 株式会社親広産業 グルコース消費促進剤および解糖系促進剤
BR112021013463A2 (pt) * 2019-01-07 2021-09-14 Saniona A/S Tesofensina para redução do peso corporal em pacientes com prader-willi
WO2021214233A1 (en) 2020-04-22 2021-10-28 Saniona A/S Treatment of hypothalamic obesity
CN117045610B (zh) * 2023-08-24 2024-04-30 杭州沐源生物医药科技有限公司 一种溶出高稳定性的盐酸拉贝洛尔组合物及其制备方法

Family Cites Families (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE141049T1 (de) 1991-03-18 1996-08-15 Sepracor Inc Zubereitung und verfahren enthaltend optisch reines s-metoprolol
ZA971525B (en) 1996-02-22 1997-10-21 Neurosearch As Tropane derivatives, their preparation and use.
US5885616A (en) * 1997-08-18 1999-03-23 Impax Pharmaceuticals, Inc. Sustained release drug delivery system suitable for oral administration
US6638937B2 (en) 1998-07-06 2003-10-28 Bristol-Myers Squibb Co. Biphenyl sulfonamides as dual angiotensin endothelin receptor antagonists
SE0100200D0 (sv) * 2001-01-24 2001-01-24 Astrazeneca Ab New film coating
DE10129725A1 (de) 2001-06-20 2003-01-02 Bayer Ag Kombinationstherapie substituierter Oxazolidinone
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
HUP0200849A2 (hu) 2002-03-06 2004-08-30 Sanofi-Synthelabo N-aminoacetil-2-ciano-pirrolidin-származékok, e vegyületeket tartalmazó gyógyszerkészítmények és eljárás előállításukra
AU2003282375A1 (en) 2003-02-05 2004-08-30 Ipca Laboratories Limited Pharmaceutical compositions and process of production thereof
OA13050A (en) 2003-04-29 2006-11-10 Pfizer Ltd 5,7-diaminopyrazolo [4,3-D] pyrimidines useful in the treatment of hypertension.
US7314640B2 (en) * 2003-07-11 2008-01-01 Mongkol Sriwongjanya Formulation and process for drug loaded cores
NZ547919A (en) 2004-01-22 2009-12-24 Neurosearch As Compounds for the sustained reduction of body weight
DE102005034351A1 (de) 2005-07-22 2007-01-25 Sension, Biologische Detektions- Und Schnelltestsysteme Gmbh Farb-Umschlag-Indikator zur Statusanzeige von RFID-Tickets und -Etiketten
US20070053983A1 (en) 2005-09-06 2007-03-08 Girish Jain Extended release compositions of metoprolol succinate
US20070092573A1 (en) 2005-10-24 2007-04-26 Laxminarayan Joshi Stabilized extended release pharmaceutical compositions comprising a beta-adrenoreceptor antagonist
WO2007073702A2 (es) 2005-12-29 2007-07-05 Osmotica Corp. Comprimido multicapa con combinación de triple liberación
US20090068260A1 (en) * 2006-02-24 2009-03-12 Tomer Gold Beta-1-selective adrenoceptor blocking agent compositions and methods for their preparation
KR20080099334A (ko) * 2006-02-24 2008-11-12 테바 파마슈티컬 인더스트리즈 리미티드 메토프로롤 숙시네이트 서방정 및 이의 제조 방법
US8815285B2 (en) 2006-03-28 2014-08-26 Wockhardt Ltd. Extended release dosage forms of metoprolol
DE102006020604A1 (de) 2006-05-02 2007-11-08 Bayer Healthcare Ag Flüssige Arzneimittelformulierung
EP2063876A1 (en) 2006-07-28 2009-06-03 Farmaprojects, S.A. Extended release pharmaceutical formulation of metoprolol and process for its preparation
EP2222302A1 (en) 2007-11-20 2010-09-01 NeuroSearch A/S A method for treating over-eating disorders
WO2009080691A2 (en) 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and an anti-obesity compound
WO2009080693A2 (en) * 2007-12-20 2009-07-02 Neurosearch A/S Pharmaceutical composition comprising tesofensine or its analogue and a beta blocker
JP2011507918A (ja) 2007-12-27 2011-03-10 バイエル・アニマル・ヘルス・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング β−遮断薬を使用する心疾患の処置
NZ595024A (en) 2009-03-11 2013-01-25 Pfizer Benzofuranyl derivatives used as glucokinase inhibitors
EA020106B1 (ru) 2009-06-05 2014-08-29 Пфайзер Инк. Производные l-(пиперидин-4-ил)пиразола в качестве модуляторов gpr119
JP5827952B2 (ja) * 2009-10-09 2015-12-02 ユンジン・ファーム・カンパニー・リミテッドＹｕｎｇｊｉｎ Ｐｈａｒｍ． Ｃｏ． Ｌｔｄ． 速効性と持続性を同時に有する薬剤学的組成物
ME02016B (me) 2009-11-02 2015-05-20 Pfizer Derivati dioksabiciklo[3.2.1]oktan-2,3,4-triola
US10485770B2 (en) 2009-12-21 2019-11-26 Aptapharma, Inc. Functionally-coated multilayer tablets
CN102145000A (zh) * 2010-02-06 2011-08-10 赤峰维康生化制药有限公司 一种坎地沙坦酯和美托洛尔复方制剂
WO2011100659A2 (en) 2010-02-12 2011-08-18 Kitov Pharmaceutical Ltd. Ameliorating drug-induced elevations in blood pressure by adjunctive use of antihypertensive drugs
CN102198112A (zh) * 2010-03-26 2011-09-28 北京天衡药物研究院 一种渗透泵型控释片及其制备方法
US8235632B2 (en) 2010-05-14 2012-08-07 Illinois Tool Works Inc. Cargo bag valve deflector
CN102762198A (zh) * 2010-05-15 2012-10-31 欢腾生命科学有限公司 多单元组合物
WO2012052834A2 (en) 2010-10-21 2012-04-26 Inventia Healthcare Private Limited Multiple unit particulate system comprising metoprolol succinate
CN102085195A (zh) * 2011-01-10 2011-06-08 中国药科大学 琥珀酸美托洛尔缓释片及其制备方法
WO2012154563A1 (en) 2011-05-06 2012-11-15 Glaxosmithkline Llc Sustained release paracetamol formulations
AU2012277375A1 (en) * 2011-06-29 2014-01-30 Sun Pharmaceutical Industries Limited Multilayered dosage form
BR112014004370A2 (pt) 2011-08-26 2017-03-21 Wockhardt Ltd métodos para tratar distúrbios cardiovasculares
CA2858522A1 (en) 2011-12-09 2013-06-13 Wockhardt Limited Methods for treating cardiovascular disorder
PL2814473T3 (pl) 2012-02-16 2019-06-28 Saniona A/S Kompozycje farmaceutyczne do terapii skojarzonej
IN2012DE00826A (ru) * 2012-03-21 2015-08-21 Ranbaxy Lab Ltd
CN102626396B (zh) * 2012-04-28 2014-05-07 海南华益泰康药业有限公司 一种美托洛尔缓释片剂及其制备方法
EP3019160A1 (en) 2013-07-09 2016-05-18 Sun Pharmaceutical Industries Ltd Extended-release pharmaceutical compositions of metoprolol
LT3265126T (lt) 2015-03-03 2021-09-10 Saniona A/S Tesofensino ir metoprololio derinio kompozicija

Also Published As

Publication number Publication date
EA033298B1 (ru) 2019-09-30
JP6772430B2 (ja) 2020-10-21
SG11201706899VA (en) 2017-09-28
US20210023050A1 (en) 2021-01-28
MX2017011257A (es) 2018-04-10
CO2017009930A2 (es) 2018-01-05
US12016840B2 (en) 2024-06-25
US20180360804A1 (en) 2018-12-20
US10828278B2 (en) 2020-11-10
US10537551B2 (en) 2020-01-21
LT3265126T (lt) 2021-09-10
MA41634B1 (fr) 2021-09-30
SA517382209B1 (ar) 2021-04-19
IL254179A0 (en) 2017-10-31
BR112017018871A2 (pt) 2018-04-17
DK3265126T3 (da) 2021-09-13
SI3265126T1 (sl) 2021-11-30
CN107666913A (zh) 2018-02-06
JP2018507875A (ja) 2018-03-22
KR20170134393A (ko) 2017-12-06
EP3265126B1 (en) 2021-06-02
MA41634A (fr) 2018-01-09
CN107666913B (zh) 2021-11-26
PT3265126T (pt) 2021-08-30
RS62275B1 (sr) 2021-09-30
PH12017501509A1 (en) 2018-02-05
CR20170447A (es) 2018-03-13
ECSP17059323A (es) 2018-06-30
WO2016138908A1 (en) 2016-09-09
PL3265126T3 (pl) 2021-12-06
UA122224C2 (uk) 2020-10-12
US20230092397A1 (en) 2023-03-23
PH12017501509B1 (en) 2018-02-05
DOP2017000219A (es) 2018-02-15
US11426383B2 (en) 2022-08-30
US10231951B2 (en) 2019-03-19
US20160279067A1 (en) 2016-09-29
EP3265126A1 (en) 2018-01-10
CL2017002214A1 (es) 2018-04-13
US20180071250A1 (en) 2018-03-15
PE20180187A1 (es) 2018-01-23
CA2977415A1 (en) 2016-09-09
IL254179B (en) 2020-11-30
HRP20211361T1 (hr) 2021-11-26
US20200129478A1 (en) 2020-04-30
US9579288B2 (en) 2017-02-28
HK1247127A1 (zh) 2018-09-21
GT201700194A (es) 2019-06-12
HUE055974T2 (hu) 2022-01-28
AU2016228002B2 (en) 2020-10-01
ES2885437T3 (es) 2021-12-13
AU2016228002A1 (en) 2017-09-14
KR101999463B1 (ko) 2019-10-01

Similar Documents

Publication Publication Date Title
EA201791875A1 (ru) Комбинированная композиция тезофензина и бета-блокатора
EA201990293A1 (ru) Мультиспецифичные антитела против cd40 и cd137
CL2017000864A1 (es) Composiciones y métodos de uso para tratar trastornos metabólicos
TW201613633A (en) Exendin-4 derivatives as selective glucagon receptor agonists
CR20160582A (es) Composición para tratar diabetes, que contienen un conjugado de análogo de insulina de acción prolongada y un conjugado de péptido insulinotrópico de acción prolongada
DOP2017000025A (es) Composiciones y métodos de uso para tratar trastornos metabólicos
EA201791420A1 (ru) Соединения триазолопиримидина и их применения
EA201691845A1 (ru) Фармацевтические композиции терапевтически активных соединений
MX2016015181A (es) Combinacion de un anticuerpo del receptor 4 de quimiocina anti-cc y un agonista de 4-1 bb para el tratamiento del cancer.
GB2541571A (en) Pharmaceutical compositions
ECSP17038999A (es) 4-oxo-3,4-dihidro-1,2,3-benzotriazinas como moduladores de gpr139
EA201691844A1 (ru) Фармацевтические композиции терапевтически активных соединений
EA201692109A1 (ru) Варианты антител к фактору d и их применение
PH12019502002A1 (en) Combination theraphy
TN2016000535A1 (en) Ppar compounds for use in the treatment of fibrotic diseases.
MX2018005987A (es) Compuestos heterociclicos para el tratamiento de enfermedades.
UY34575A (es) Composiciones y métodos para el tratamiento de diabetes y/u obesidad
PH12017500910A1 (en) Use of sigma receptor ligands in osteoarthritis
MX2023008839A (es) Composicion de liberacion tardia de linaclotida para uso en el tratamiento de trastornos gastrointestinales.
HUE053924T2 (hu) Kompozíció cukorbetegség kezelésére
AR103830A1 (es) Formulación de combinación de tesofensina y betabloqueante
MX2017000087A (es) Compuestos rexinoides y metodos para utilizar compuestos rexinoides para tratar trastornos metabolicos y cancer.
PH12016502466A1 (en) Ppar compounds for use in the treatment of fibrotic diseases
CL2015001705A1 (es) Uso de pidotimod para tratar la psoriasis
EA201401235A1 (ru) Композиция, содержащая глюкозамин, фруктобарат кальция и витамин d для лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов, её применение и способ лечения и/или профилактики нарушений, связанных с воспалительными заболеваниями суставов и позвоночника